Peterschmitt M J, Simmons J R, Levy H L
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
N Engl J Med. 1999 Nov 18;341(21):1572-6. doi: 10.1056/NEJM199911183412103.
Mental retardation and other disabilities (including ectopia lentis, osteoporosis, and thromboembolism) in patients who have homocystinuria as a result of a deficiency of cystathionine beta-synthase can be prevented by the screening of newborns with measurement of blood methionine, followed by the early treatment of affected infants. Many infants with this disorder, however, are not identified by screening and have irreversible brain damage.
We reviewed the results of neonatal screening for homocystinuria over a period of 32 years in New England. Additional specimens were requested for repeated analysis when blood methionine measurements were at or above the established cutoff level. Homocystinuria due to cystathionine beta-synthase deficiency was confirmed by quantitative amino acid analyses.
For the first 23.5 years of the review period, the blood methionine cutoff value was 2 mg per deciliter (134 micromol per liter). Among the 2.2 million infants screened during that period, 8 with homocystinuria were identified (1:275,000). In 1990, the cutoff value was reduced to 1 mg per deciliter (67 micromol per liter). Among the 1.1 million infants screened in the subsequent 8.5 years, 7 with the disorder were identified (1:157,000). During the latter period, the specimens were collected from six of the seven infants when they were two days of age or less; five of the six had blood methionine concentrations below 2 mg per deciliter. Use of the reduced cutoff level increased the false positive rate from 0.006 percent to 0.03 percent.
A cutoff level for blood methionine of 1 mg per deciliter in neonatal screening tests for homocystinuria should identify affected infants who have only slightly elevated concentrations of methionine and reduce the frequency of false negative results.
由于胱硫醚β合成酶缺乏导致同型胱氨酸尿症的患者出现的智力发育迟缓及其他残疾(包括晶状体异位、骨质疏松和血栓栓塞),可通过检测血蛋氨酸对新生儿进行筛查,并对患病婴儿进行早期治疗来预防。然而,许多患有这种疾病的婴儿未通过筛查被识别出来,从而导致不可逆的脑损伤。
我们回顾了新英格兰地区32年间新生儿同型胱氨酸尿症筛查的结果。当血蛋氨酸测量值达到或高于既定临界值时,要求采集额外样本进行重复分析。通过定量氨基酸分析确诊因胱硫醚β合成酶缺乏导致的同型胱氨酸尿症。
在回顾期的前23.5年,血蛋氨酸临界值设定为每分升2毫克(每升134微摩尔)。在此期间筛查的220万婴儿中,发现8例同型胱氨酸尿症患者(1:275,000)。1990年,临界值降至每分升1毫克(每升67微摩尔)。在随后的8.5年里筛查的110万婴儿中,发现7例患有该疾病(1:157,000)。在后一时期,7例婴儿中有6例在出生两天及以内采集了样本;6例中的5例血蛋氨酸浓度低于每分升2毫克。使用降低后的临界值使假阳性率从0.006%增至0.03%。
在新生儿同型胱氨酸尿症筛查试验中,血蛋氨酸临界值设定为每分升1毫克应能识别出血蛋氨酸浓度仅轻度升高的患病婴儿,并减少假阴性结果的发生频率。